Märkte & Kurse

    ^
Original-Research: Eckert & Ziegler SE - from NuWays AG

05.02.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS
Group.
The issuer is solely responsible for the content of this research. The
result of this research does not constitute investment advice or an
invitation to conclude certain stock exchange transactions.

---------------------------------------------------------------------------

Classification of NuWays AG to Eckert & Ziegler SE

     Company Name:                Eckert & Ziegler SE
     ISIN:                        DE0005659700

     Reason for the research:     Update
     Recommendation:              BUY
     Target price:                EUR 23
     Target price on sight of:    12 months
     Last rating change:
     Analyst:                     Simon Keller

Picks and shovels play intact, chg.

Novo Nordisk's c.17% share price drop underscores how quickly sentiment can
turn in single product healthcare stories, especially when patent cycle
concerns resurface. In contrast, EUZ is "picks and shovels" by design,
supplying regulated radioisotopes and services across a broad set of nuclear
medicine applications. The moat is built on execution and regulatory
qualification, not a single patent protected product, implying limited
binary risks.

FY25 prelims underline this quality profile. In Q4 25, sales came in at EUR
87.9m (+9% yoy, eNuW: EUR 91.3m), with reported growth held back by c. 3-4pp
fx-headwinds (eNuW). Adj. EBIT rose 41% yoy to EUR 27.2m (eNuW: EUR 23.2m),
taking the adj. EBIT margin to 31% (+7pp yoy), likely reflecting a better
mix (e.g. c.EUR 10m license sales, vs. EUR 5m last year, eNuW). With this, Q4
confirms the strengthening earnings momentum, supporting confidence into
2026e, where we expect 7% yoy sales growth (adj. for license sales: 11%
yoy), driven by a 12% yoy improvement in radiopharma (eNuW, adj. for license
sales: 20% yoy).

Additional supportive newsflow from China: Telix has filed its PSMA PET
prostate cancer imaging product Illuccix, utilising Ga-68, and the dossier
has been accepted for review. While this is not an approval yet, it is a
tangible step toward opening up a large new market. This is supportive for
EUZ's Ga-68 growth leg (eNuW: c.21% of group sales). It also fits a broader
pattern of Ga-68 utilising players progressing in China, including Novartis,
where an approval decision is pending for their product, to our knowledge.
More broadly, driven by international expansion and earlier use in the
patient pathway, we expect the Ga-68 market to roughly double by 2030e
(eNuW), and see scope for EUZ's related revenues to scale accordingly.

Separately, EUZ quantified the growth runway in therapeutic isotopes for
prostate cancer and neuroendocrine tumours at recent conferences:

  * Lu-177: EUZ sees treated patients rising to c.75k by 2030e (from c.20k
    in 2025e), with the Lu-177 market potential scaling to EUR >600m (from EUR
    >160m in 2025) over the same period.

  * Ac-225: By 2034e, EUZ sees treated patients reaching c.13k, with the
    implied Ac-225 market potential of EUR >205m.


These market potential figures reinforce the therapeutic isotope upside
embedded in EUZ. From a low base (eNuW: low single digit EURm in 2025e for
Lu-177 plus Ac-225 combined, excl. license fees), EUZ should participate as
volumes industrialise, given its proven supplier positioning. We model at
least EUR 25m sales each for Lu-177 and Ac-225 by 2030e, supporting the long
term growth angle. BUY, unchanged PT of EUR 23, based on DCF.


You can download the research here:
https://eqs-cockpit.com/c/fncls.ssp?u=a3eb2469e11d377cb231791fc6f544e4
For additional information visit our website:
https://www.nuways-ag.com/research-feed

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss
bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben
analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++

---------------------------------------------------------------------------

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
View original content:
https://eqs-news.com/?origin_id=12350f16-0266-11f1-8534-027f3c38b923&lang=en

---------------------------------------------------------------------------

2271774 05.02.2026 CET/CEST

°